Integumen PLC LabskinAI creates virtual AI psoriasis skin model (8714O)
07 October 2019 - 5:00PM
UK Regulatory
TIDMSKIN
RNS Number : 8714O
Integumen PLC
07 October 2019
AIM share code: SKIN
7 October 2019
Integumen PLC
("Integumen" or "Company")
LabskinAI team create a virtual AI psoriasis skin model
Integumen announces that at the AI Awards 2019 event, in Dublin,
the LabskinAI combined teams of microbiology and computer science
disclosed the completion of an artificially intelligent, virtual
psoriasis skin model.
Utilising 671 anonymised patients, samples were taken directly
from the Psoriasis lesion and other sites on the patients with
psoriasis with a goal to produce an AI generalised solution for
diseased skin. Following genomic sequencing of the samples, the
resulting datasets identified 216 species of microbiota (bacteria,
virus and fungi). These were confirmed using a number of different
AI algorithms.
Following the testing of various types, a reliable psoriasis
model was identified and was confirmed through a cross-validation
process. In total, 33 species were identified that are critical to
the success of the Labskin AI diseased skin model for analysing
psoriasis. The continued addition of patient data will further
increase the accuracy of the psoriasis model. This AI dataset model
can also be used to develop other diseased skin models such as
atopic dermatitis, rosacea and acne.
Substantial development cost and time saving
Studies estimate that Psoriasis affects up to 4.8 % of global
population[i]. The economic burden of this disease in the health
care system is significant. In 2008, the annual cost of psoriasis
in the USA was estimated at $11.25 Billion[ii]. On the other hand,
the burden of atopic dermatitis in the USA was $5.297 in 2015, with
a of 10.7% of children and 7.2% of adults affected[iii]. In Europe
the number of children showing symptoms of atopic dermatitis
oscillate between 10 % and 20%[iv].
The cost of new topical drugs is costly and it can take 10 to 15
years at a cost of GBP2 billion per new drug[v] and has a failure
rate of 95%[vi]. LabskinAI is ethical, as there is no requirement
to set up expensive pre-clinical animal trials. Pharmaceutical
companies can undertake topical treatment and skin care product
tests in weeks with the LabskinAI diseased skin models that mimic
the human skin, in the laboratory.
Gerard Brandon - CEO of Integumen plc, comments:
"Integumen is at the forefront of AI development for the skin
care industry. AI diseased skin models are the new frontier and are
a disruptive platform for new drug discovery. This has the ability
to transform the research and development of diseased skin
treatments, making them a lot less expensive and bring products to
the market faster. This is why large skin care companies are
signing up to use LabskinAI, as reported in the RNS issued earlier
today"
Contacts
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Andrew
(Nominated Adviser) Emmott +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments Andy Thacker/Zoe
(TPI) Limited (Broker) Alexander +44 (0) 20 3657 0050
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated product and services
company for skin related diseases, treatments and therapies with
three business units:
-- Labskin AI's technology platform incorporates artificial
intelligence within clinical research for medical device,
pharmaceuticals, cosmeceuticals and related life science test
services. Labskin allows skincare, healthcare, pharmaceutical
manufacturers and cosmetic companies to test their products on
human-like skin in a real-world environment with full access to
multiple state-of-the-art partner technologies.
-- Wound pHase is developing skin and wound care products using
its proprietary wound dressing technology. Working in collaboration
with CBD providers creating a CBD infused diabetic wound care
product range.
-- Stoer-for-men skin products e-commerce division offers a
range of skincare products derived from 5 natural super-ingredient
plant extracts specifically for men to reduce the signs of ageing
and is also used as a control for client testing within Labskin
laboratories.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
[i]https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis;jsessionid=54912784D28C9F36ECCD45471AC5775B?sequence=1
[ii] WHO Library Cataloguing-in-Publication DataGlobal report on
psoriasis.1.Psoriasis - epidemiology. 2.Psoriasis - prevention and
control. 3.Public Health. 4.Skin Diseases. I.World Health
Organization.ISBN 978 92 4 156518
[iii] Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi
AA.The Burden of Atopic Dermatitis: Summary of a Report for the
National Eczema Association. J Invest Dermatol. 2017
Jan;137(1):26-30. doi: 10.1016/j.jid.2016.07.012. Epub 2016 Sep
8.
[iv] Kowalska-Ol dzka E, Czarnecka M, Baran A. Epidemiology of
atopic dermatitis in Europe. J Drug Assess. 2019 Jun
12;8(1):126-128. doi: 10.1080/21556660.2019.1619570. eCollection
2019. Review
[v]
https://www.sciencedirect.com/science/article/abs/pii/S0167629616000291?via%3Dihub
[vi]
https://www.pharmaceutical-technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESFSEFDLFUSELS
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024